What Researchers Did
Researchers conducted a multicentre, prospective cohort study to investigate the prevalence of middle ear barotrauma and tympanic membrane bleeding during hyperbaric oxygen treatment in patients using antiplatelet/anticoagulant drugs compared to controls.
What They Found
Among 73 patients undergoing hyperbaric oxygen treatment, mild middle ear barotrauma occurred in 23 of 34 patients using antiplatelet/anticoagulant drugs and in 31 of 39 control patients. High-grade barotrauma (Teed score 3) was rare, occurring in only two control patients and none of the drug-treated patients, though two anticoagulant users reported epistaxis.
What This Means for Canadian Patients
Canadian patients undergoing hyperbaric oxygen treatment should be aware that mild middle ear barotrauma is a common occurrence, regardless of antiplatelet or anticoagulant use. While high-grade ear bleeding appears rare with current procedures, patients on anticoagulants should discuss any previous bleeding complications like nosebleeds with their care team.
Canadian Relevance
This study has no direct Canadian connection as it was conducted in a different country and does not involve Canadian participants or healthcare systems.
Study Limitations
The relatively small sample size and the study's inability to definitively conclude on the increased risk of haemorrhagic complications in drug users are limitations.